David Fei
Overview
Explore the profile of David Fei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spartano N, Prescott B, Walker M, Shi E, Venkatesan G, Fei D, et al.
J Diabetes Sci Technol
. 2025 Feb;
:19322968251315171.
PMID: 39936548
Background: Clinical interpretation of continuous glucose monitoring (CGM) data for people without diabetes has not been well established. This study aimed to investigate concordance among CGM experts in recommending clinical...
2.
Defining continuous glucose monitor time in range in a large community-based cohort without diabetes
Spartano N, Sultana N, Lin H, Cheng H, Lu S, Fei D, et al.
J Clin Endocrinol Metab
. 2024 Sep;
PMID: 39257191
Context: Continuous glucose monitor (CGM) companies are beginning to market these sensors to populations without diabetes, but the range of CGM values clinicians should expect to see for this population...
3.
Lai C, Parnell L, Smith C, Guo T, Sayols-Baixeras S, Aslibekyan S, et al.
Am J Clin Nutr
. 2020 Sep;
112(5):1200-1211.
PMID: 32930325
Background: Epigenome-wide association studies identified the cg00574958 DNA methylation site at the carnitine palmitoyltransferase-1A (CPT1A) gene to be associated with reduced risk of metabolic diseases (hypertriglyceridemia, obesity, type 2 diabetes,...
4.
Weiwer M, Xu Q, Gale J, Lewis M, Campbell A, Schroeder F, et al.
ACS Chem Biol
. 2018 Feb;
13(4):1038-1047.
PMID: 29485852
Schizophrenia is a severe neuropsychiatric disease that lacks completely effective and safe therapies. As a polygenic disorder, genetic studies have only started to shed light on its complex etiology. To...
5.
Wagner F, Bishop J, Gale J, Shi X, Walk M, Ketterman J, et al.
ACS Chem Biol
. 2016 Apr;
11(7):1952-63.
PMID: 27128528
The mood stabilizer lithium, the first-line treatment for bipolar disorder, is hypothesized to exert its effects through direct inhibition of glycogen synthase kinase 3 (GSK3) and indirectly by increasing GSK3's...
6.
Gaudreault J, Fei D, Beyer J, Ryan A, Rangell L, Shiu V, et al.
Retina
. 2007 Nov;
27(9):1260-6.
PMID: 18046235
Purpose: Ranibizumab (Lucentis) is a humanized antigen-binding fragment designed to inhibit all isoforms and active degradation products of vascular endothelial growth factor A (VEGF-A); it is in clinical development for...
7.
McCutcheon K, OHara E, Fei D
Immunol Invest
. 2005 Jun;
34(2):199-213.
PMID: 15921159
Analytical methods characterizing the immunogenicity of therapeutic proteins are useful for monitoring, characterizing and predicting reactions to biopharmaceuticals. A multiplexed assay capable of isotyping the specific IgG, IgA, IgM and...
8.
Wang Y, Fei D, Vanderlaan M, Song A
Angiogenesis
. 2005 May;
7(4):335-45.
PMID: 15886877
Bevacizumab (Avastin, Genentech) is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), a critical angiogenic factor involved in both physiological and pathological conditions. It has been recently approved...
9.
Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V
Invest Ophthalmol Vis Sci
. 2005 Jan;
46(2):726-33.
PMID: 15671306
Purpose: Ranibizumab (rhuFab V2; Lucentis, Genentech, South San Francisco, CA) is a humanized monoclonal antibody fragment designed to bind all forms of VEGF, thereby blocking vessel permeability and angiogenesis in...